

THE ⁴⁸¹¹
BRITISH JOURNAL
OF
VENEREAL DISEASES

HONORARY EDITOR

V. E. LLOYD, *M.C.*, *M.B.*, *B.S.*

VOL. XXI

March, 1945 to December, 1945



Published by
BUTTERWORTH & CO. (PUBLISHERS) LTD
4, 5, 6 BELL YARD, TEMPLE BAR, W.C.2

64554



CONTENTS

	PAGE
EDITORIAL	1
VENEREAL DISEASES IN THE SOVIET UNION	
By J. A. SCOTT, O.B.E., M.D.	2
DISCUSSION	7
THE SECONDARY REACTION IN TWENTY-DAY INTENSIVE ARSENO- THERAPY	
By ROBERT H. CREDE, Capt., U.S.A.M.C.	9
THE SOCIAL ASPECT OF THE VENEREAL DISEASES—1	
By DOROTHY M. MANCHÉE	12
THE SOCIAL ASPECT OF THE VENEREAL DISEASES—2	
By MARGARET A. WAILES	15
THE SOCIAL ASPECT OF THE VENEREAL DISEASES—3	
By HILDA M. JOHNS, M.A.	17
DISCUSSION ON THE PRECEDING PAPERS	21
THE SOCIAL BACKGROUND OF VENEREAL DISEASE—TYNESIDE EXPERIMENTAL SCHEME IN VENEREAL DISEASE CONTROL, OCTOBER 1943 TO MARCH 1944	26
“MIDDLE EAST GRANULOMA”: IS IT GRANULOMA VENEREUM?	
By W. R. SCOTT COWE, M.B., Ch.B.	34
DIFFICULTIES IN THE SUCCESSFUL TREATMENT OF THE VENEREAL DISEASE PATIENT	
By DAVID ERSKINE, M.D., D.P.H.	47
DISCUSSION	56
ACQUIRED SYPHILIS IN CHILDREN—THREE PROBABLE CASES	
By R. C. WOFINDEN, M.D., D.P.H.	60
AMBULATORY TREATMENT OF EARLY SYPHILITIC INFECTION WITH PENICILLIN	
By T. R. LLOYD JONES, M.R.C.S., L.R.C.P., and F. GORDON MAITLAND, M.R.C.S., L.R.C.P.	65
DISCUSSION	75
THE SUITABILITY OF KAHN ANTIGENS FOR THE TECHNIQUE USED IN THE CITROCHOL REACTION	
By J. H. NELSON, M.Sc., Ph.D. (Dublin) and H. SACHS, M.D., M.Sc., Ph.D. (Dublin)	78

CONTENTS

	PAGE
A RAPID MICROSCOPICAL METHOD FOR THE SERODIAGNOSIS OF SYPHILIS	
By M. SEILER, M.D. (Lwow)	82
INVESTIGATIONS IN THE SERODIAGNOSIS OF SYPHILIS	
By L. HANDLEY ASHKEN	84
THE CUTANEOUS MANIFESTATIONS OF GONORRHOEA	
By A. H. HARKNESS, M.R.C.S., L.R.C.P.	93
DISCUSSION	113
AURAL SYPHILIS	
By T. RITCHIE RODGER, O.B.E., M.D., F.R.C.S.Ed.	115
TREATMENT OF VENEREAL DISEASES IN THE ALLIED MERCHANT NAVIES	
By A. O. F. ROSS, M.D., D.P.H.	123
PENICILLIN THERAPY OF EARLY SYPHILIS	
By DONALD M. PILLSBURY, M.D.	139
THE TREATMENT OF GONORRHOEA WITH PENICILLIN	
By J. MARSHALL, M.D.	150
DISCUSSION ON THE PRECEDING PAPERS	156
GUMMA OF THE THYROID GLAND	
By SYDNEY M. LAIRD, B.Sc., M.D., Ch.B., F.R.F.P.S., D.P.H.	162
INTENSIVE ARSENOTHERAPY OF EARLY SYPHILIS	
By T. R. LLOYD JONES, M.R.C.S., L.R.C.P. and F. GORDON MAITLAND, M.R.C.S., L.R.C.P.	166
DISCUSSION	172
ANNOTATIONS	
THE JARISCH-HERXHEIMER REACTION	
By V. E. LLOYD, M.C., M.B., B.S.	42
PODOPHYLLIN TREATMENT OF GENITAL WARTS	
By H. HABER, M.D. (Prague)	63
COINCIDENTAL SYPHILIS AND GONORRHOEA	
By E. CRONIN, M.D.	135
ORAL ADMINISTRATION OF BISTOVOL IN GENERAL PARALYSIS	
By R. PAKENHAM-WALSH, D.M., D.P.M.	174

CONTENTS

	PAGE
SYPHILIS IN SEVENTEENTH CENTURY LANCASHIRE	
By R. SHARPE FRANCE, F.R.Hist.S., and A. FESSLER, M.R.C.S., L.R.C.P., M.D. (Vienna)	177
GENITAL OEDEMA IN RELATION TO FILARIASIS IN THE GOLD COAST	
By R. R. WILLCOX, Major, R.A.M.C.	178
CLINICAL RECORDS	
A FATAL CASE OF PURPURA HAEMORRHAGICA WITH AGRANU- LOCYTIC ANGINA AFTER ARSPHENAMINE THERAPY	
By P. C. P. INGRAM, M.B., B.S., and E. GRAHAME JONES, M.B., M.R.C.P. ...	40
SUBCUTANEOUS FIBROID SYPHILOMATA	
By A. F. GRANGER, M.B., Ch.B., and S. M. LAIRD, M.D., D.P.H.	86
DIAGNOSIS OF SYPHILIS AFTER PENICILLIN *TREATMENT FOR GONORRHOEA	
By Surg. Cdr. BRIAN WESTON	87
REVIEWS OF BOOKS	44, 88, 137, 179
CORRESPONDENCE	45, 91, 137
EDITORIAL NOTES	46, 92, 138, 180

TWENTY-DAY INTENSIVE ARSENOTHERAPY

injection. They are not severe, however, and the patient usually feels well on the following morning.

(2) *Severe reaction.* The second type is the fever that accompanies a severe secondary reaction, which may range from 103°-105° F. for 3-5 days. In this type of reaction one sees the serious complications: toxicodermal reactions, hepatitis, encephalopathy and agranulocytosis. These patients present a more difficult problem. It is our practice to wait from 4-6 days after the patient has become afebrile and symptom-free and then, if there has been no serious complication, to resume treatment with a 0.0006-gramme dose of mapharsen. This is approximately one-hundredth of the usual dose and is given in 10 cubic centimetres of distilled water, as described above. The amount of mapharsen is doubled daily until the patient tolerates the full dose without ill effect. During the period of small dosage the patient may suffer an exacerbation of his earlier symptoms but, as in the previous regime, he usually feels well the following morning. If, however, the reaction has been severe, the same dose may be given for a second time before the amount is doubled.

Conclusions

As the result of our experience we have been able to formulate a few simple therapeutic principles in regard to the secondary reaction and the subsequent treatment of the patient.

(1) If a patient has had a severe secondary reaction and treatment is resumed with a 0.006-gramme dose of mapharsen, the ensuing reaction may be as severe as was the original and may discourage the clinician from further treatment. When in doubt it is wise to resume treatment with a 0.0006-gramme dose of mapharsen.

(2) If treatment has been interrupted for some reason other than a secondary reaction, it is unwise to resume treatment with a full dose, as the patient is apt to have a reaction of the secondary type. It is our practice to resume treatment with a 0.006-gramme dose and the amount is increased daily as in the case of a moderately severe secondary reaction.

(3) After close observation we have been unable to discover any ill effects as the result of continuing treatment in patients who have had a severe secondary reaction.

(4) As far as we can determine, the only contraindications for further intensive arsenotherapy after the occurrence of a secondary reaction are the following: (a) hepatitis, (b) proved encephalopathy with persistence of symptoms and abnormal spinal fluid findings and (c) severe blood dyscrasias. For a patient of this type treatment may be continued with penicillin instead of the arsenicals.

By the use of the methods described above it has been possible to complete the twenty-day intensive course of treatment of 424 out of 428 patients.

MEDICAL SOCIETY FOR THE STUDY OF VENEREAL DISEASES

PROGRAMME OF MEETINGS, 1945

All meetings are held at 11 Chandos Street, Cavendish Square, London, W.1, on Saturdays, at 2.30 p.m.

- March 24th Subject: *Early syphilitic infection treated with intensive arsenotherapy and penicillin.*
Speakers: Surg. capt. T. R. Lloyd-Jones and Surg. cmdr. F. G. Maitland.
- April 28th Subject: *Cutaneous manifestations in gonorrhoea.*
Speaker: Dr. A. H. Harkness.
- May 26th Subject: *The treatment of infective arthritis with special reference to hyperthermia.*
Speakers: Lt.-col. A. J. King, Maj. C. S. Nichol and Maj. D. I. Williams.
- July 28th ANNUAL GENERAL MEETING:
Subject: *Optimal methods of treatment of the venereal diseases with penicillin.*
Speakers: Col. D. M. Pillsbury and Maj. J. Marshall.

THE BRITISH JOURNAL OF VENEREAL DISEASES

previous communications in the literature on this subject. I trust that Brig., Osmond and Dr. Price will add it to their long lists of infective foci teeming with gonococci yet giving negative serum reactions.

London, W.1

A. H. HARKNESS

REFERENCES

- Barrington, F. J. F., and Wright, H. D. (1930) *J. Path. Bact.*, 33, 871.
Bockhart, M. (1883) *Arch. Derm. Syph., Wien*, 15, 3.
Bumm, E. (1885) *Der Mikro-Organismus der gonorrhöischen Schleimhaut-Erkrankungen*, J. F. Bergmann, Wiesbaden.
Burnet, F. M. (1941) *Production of Antibodies*, Macmillan & Co., London.
Carpenter, C. M. (1937) *J. Amer. med. Ass.*, 109, 1428.
Finger, E., Ghon, A., and Schlagenhauer, F. (1894) *Arch. Derm. Syph., Wien*, 28, 277.
Jacoby, W. M. (1924) *Verh. dtsh. Ges. Urol.*, 6, 310.
Jacoby, A., and Wishengrad, M. (1937) *Neisserian med. Soc.*, pp. 10-20.
Lever, W. F., and Crawford, G. M. (1944) *Arch. Derm. Syph., N.Y.*, 49, 389.
Sawyer, W. A. (1931) *J. prev. Med.* 5, 413.
Walker, K. M. (1913) *Lancet*, 1, 435.

Sir,—Two points in Dr. Harkness's letter seem to merit a reply. First, I am surprised that Dr. Harkness says that he has not been invited to Whitechapel. However, may I repeat the invitation? Secondly, his remarks concerning the lifelong immunity conferred by attacks of measles, yellow fever, diphtheria, and scarlet fever, and the demonstration of the respective antibodies long after the infection has ceased, refer to well-known facts. What is odd is that he uses these facts in order to bolster up his contention that the production of gonococcal antibodies may proceed unhindered long after the infection has been eradicated. Does he contend that an attack of gonorrhoea confers a lifelong immunity to the disease? If not, I fail to see the point of his analogy.

In conclusion, I would suggest that Dr. Harkness would be doing a bigger service to his colleagues if he were to put forth some constructive criticism, instead of decrying this test on the strength of hazy clinical impressions and some hand-picked quotations.

London, W.1

I. N. ORPWOOD PRICE

EDITORIAL NOTES

The Editors beg to acknowledge with thanks the receipt of the following periodicals, etc.

American Journal of Syphilis

British Journal of Dermatology and Syphilis

British Journal of Urology

British Medical Journal

Cronica Medica

Journal of the Cape Town Post-Graduate Medical Association

Journal of Experimental Medicine

Medicina Española

New England Journal of Medicine

Revista de la Asociación Médica Argentina

Revista de medicina Tropical y Parasitología Bacteriología clinica y

Laboratio

Revista de Sanidad y Asistencia Social

Revista del Instituto de Salubridad y enfermedades tropicales

Revista médica de Chile

Revista médica de Yucatan

South African Journal of Medical Sciences

Urologic and Cutaneous Review

Veneral Disease Information